8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 12, 2026·SEC
Corbus Pharmaceuticals Holdings, Inc.(CRBP)Earnings, Financials & Key Ratios
CRBP•NASDAQ
$9.00
Price updated Jul 6, 2026
AboutCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Show more
- Revenue$0
- EBITDA-$85M-76.8%
- Net Income-$79M-95.3%
- EPS (Diluted)-5.90-60.3%
- ROE-54.18%+8.7%
CRBP Price & Volume
Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock price & volume — 10-year historical chart
Loading chart...
Escalating Clinical Burn Pressures Corbus Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding exhaustion
Key Thesis Takeaways
- Corbus Pharmaceuticals remains in a high-risk, pre-revenue development phase, with its valuation entirely dependent on the successful advancement of its oncology and metabolic pipeline.
- The company's reliance on equity-based financing to cover rising R&D costs, which reached $19.8 million in 2026Q1, creates significant dilution risk for existing shareholders.
- Investors should monitor the company's ability to achieve critical clinical milestones before the current $26.0 million cash position is exhausted, as the lack of commercial revenue leaves little margin for operational error.
Verdict Logic
the company's persistent quarterly cash burn of $25.6 million and lack of commercial revenue suggest a high probability of further shareholder dilution to maintain operations.
CRBP Growth Metrics
Corbus Pharmaceuticals Holdings, Inc. (CRBP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-68.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM3.93%
Return on Capital
10 Years-151.8%
5 Years-85.16%
3 Years-102.68%
Last Year-58.52%
CRBP Recent Earnings
Corbus Pharmaceuticals Holdings, Inc. (CRBP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$1.23+2.4%
$1.26
Rev
—
—
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$1.25+29.8%
$1.78
Rev
—
$2M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$1.90-5.6%
$1.80
Rev
—
$1M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$1.44+7.1%
$1.55
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $1.23vs $1.26+2.4% | — |
| Q2 2026 | Mar 9, 2026 | $1.25vs $1.78+29.8% | —vs $2M |
| Q4 2025 | Nov 12, 2025 | $1.90vs $1.80-5.6% | —vs $1M |
| Q3 2025 | Aug 5, 2025 | $1.44vs $1.55+7.1% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Corbus Pharmaceuticals Holdings, Inc. (CRBP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.00 | $112.82M | -1.53 | — | — | -54.18% | — | |
| $37.39 | $2.22B | -5.25 | 48.03% | -639.84% | -34.11% | — | |
| $29.98 | $3.02B | -9.11 | -4.26% | -156.36% | -68.97% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $26.07 | $3.26B | -200.54 | 91.34% | -0.57% | -1.41% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — |
Compare CRBP vs Peers
Corbus Pharmaceuticals Holdings, Inc. (CRBP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRBP SEC Filings & Documents
Corbus Pharmaceuticals Holdings, Inc. (CRBP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CRBP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRBP Frequently Asked Questions
Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CRBP profitable?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported a net loss of $84.5M for fiscal year 2025.
Dividend & Returns
What is CRBP's return on equity?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a return on equity (ROE) of -54.2%. Negative ROE indicates the company is unprofitable.
What is Corbus Pharmaceuticals Holdings, Inc.'s free cash flow?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had negative free cash flow of $73.7M in fiscal year 2025, likely due to heavy capital investments.